US 6040193

I'll verify this against live sources before summarizing.

Verification run (April 26, 2026)

---

Abstract

Third‑party databases (FreePatentsOnline, Justia Company Profiles) report the abstract verbatim as:

"An array is created by moving a dispenser toward a solid support until a tip of the dispenser touches the support, withdrawing the tip from the surface and releasing a drop of 5 nanoliters or less in an area smaller than 1 mm² to create an array of at least 100 spots."

This is consistent with the spotting/droplet-delivery disclosure in the body of the specification (e.g. "a conventional micropipetting instrument is adapted to dispense droplets of five nanoliters or smaller from a capillary," and "the dispenser tip preferably will be located about 5–50 µm above the substrate surface when a five nanoliter drop is released"). Note that the Google Patents "Definitions"/description text supplied is the long Combinatorial strategies disclosure (channel-block flow synthesis, resist/photoactivated regions, spotting, dispenser registration), which is the common specification shared across this continuation family — the abstract above is narrower than the specification.

---

Plain-language overview of the independent claims

I must flag a hard limit here. The specification text I was given is truncated before the claims, and my searches this session returned only the granted claim 1 text of sibling patents, not of 6,040,193 itself. Specifically:

• I verified claim 1 of US 6,849,462 (app. 09/579,991) — resist-deposit/selective-removal, dispense first monomer into localized areas < 1 cm², repeat until ≥ 10 different polymers.
• I verified claim 1 of US 6,864,101 (app. 09/579,949) — automated spotting, ≤ 5 nl per coupling step, ≥ 100 different ligands, ≥ ~1000 localized areas/cm².

Both are continuations of 09/498,554 → 09/129,463 (now 6,040,193). I did not retrieve an authoritative copy of the literal claim set (claim 1 et seq.) of 6,040,193. I will not fabricate it.

What can be said with confidence about the independent claims, based on the reported abstract plus the family lineage:

1. A dispenser-tip contact/withdrawal spotting method (most likely the sole or dominant independent claim family). In plain language: an automated dispenser is brought down to the support until its tip contacts the surface, then backed off a fixed distance; a droplet of ≤ 5 nL is released into a defined area smaller than 1 mm²; the process is repeated at enough locations to build an array of ≥ 100 spots. The transfer/deposition is metered by the dispenser rather than by a channel block or a photolithographic mask.
2. Ancillary independent claims in the family (as seen in the sibling patents) recite (a) resist-defined localized areas — deposit a resist, selectively remove it to expose the area, dispense monomer, repeat until an array of multiple different polymers forms; and (b) quantitative density caps — ≤ 5 nL per single coupling step, ≥ 100 different ligands, ≥ ~1000 areas/cm². Whether 6,040,193 itself carries all three, or only the spotting variant, is unverified.

---

Prosecution family (from the priority/continuation records)

Continuation chain as recited in the Official Gazette entries for the children (interpreted literally, including an apparent inconsistency I am not correcting):

• 07/796,243 (1991‑11‑22) → US 5,384,261
• 07/874,849 (1992‑04‑24) → US 5,412,087
• 07/980,523 (1992‑11‑20) → US 5,677,195
• 08/426,202 (1995‑04‑21) → US 6,136,269
• 09/129,463 (1998‑08‑04) → US 6,040,193
• 09/498,554 (2000‑02‑04) → US 6,943,034
• 09/579,991 / 09/579,949 / 09/579,982 (2000‑05‑26) → US 6,849,462 / 6,864,101 / 7,691,330
• Later: US 7,736,906 B2; publications US 2005/0186683, 2005/0124000, 2005/0186592

Reported inconsistency (not corrected): the OG text for US 6,864,101 states that 07/796,243 "is a continuation‑in‑part of application No. 07/874,849, filed on Apr. 24, 1992" — which would make the parent file after the child. Other records in the same chain describe 07/980,523 as the CIP of 07/796,243. Under your rule I have left both as reported.

---

Litigation

• Affymetrix, Inc. v. Synteni, Inc. and Incyte Pharmaceuticals, Inc., N.D. Cal. Case Nos. C 99‑21164 JF and C 99‑21165 JF — the second suit asserted, among others, U.S. Pat. Nos. 5,871,928 and 6,040,193. (Investor/Incyte and SEC filings.) Also reported as involving Incyte Genomics, Inc. v. Affymetrix, Inc., C 01‑20065 JF.
• Settled December 21, 2001 — Incyte and Affymetrix announced a comprehensive settlement of all existing infringement litigation, with non‑exclusive, royalty‑bearing cross‑licenses and an internal-use license under the respective portfolios. The press release version of the announcement lists the asserted Affymetrix patents as 5,445,934, 5,744,305, 5,800,992, 5,871,928 and 6,040,193.
• The Google Patents page carries the Darts‑IP banner "Family has litigation," consistent with the above, but that banner alone does not identify 6,040,193 as the asserted patent.
• CAFC 2026 dockets: I found no Court of Appeals for the Federal Circuit 2026 docket entry naming 6,040,193. This is expected — the patent is recorded as expired (anticipated expiration 2011‑11‑22), which would normally moot infringement appeals. I could not query an authoritative CAFC docket system directly in this session, so treat "no 2026 CAFC activity" as no evidence found, not as a certified negative.

---

Uncertainty statement

1. Claim text of 6,040,193 itself is unverified. The abstract, title, dates, assignee and inventors are corroborated across Google Patents, FreePatentsOnline, Justia and the Official Gazette lineage records. The literal wording and count of the independent claims is not corroborated and should be pulled from the USPTO PatentCenter/Patent Public Search full‑text of 6,040,193 before it is relied on. My plain-language overview is an inference from the reported abstract and the sibling continuations, and is labelled as such.
2. Search scope. My queries hit Google Patents, FreePatentsOnline, Justia, IP.com/USPTO-report mirrors, Indiana University's OG mirror, Incyte investor filings and GenomeWeb. I did not have direct interactive access to USPTO PatentCenter or the CAFC docket in this session.
3. No similar numbers substituted. Everything above refers only to 6,040,193 (app. 09/129,463). References to 6,849,462, 6,864,101, 6,943,034, 7,691,330, 5,384,261, 5,412,087, 5,677,195, 6,136,269 and 5,871,928 are cited solely as family/litigation context, not as substitutes.

I'll search for litigation records involving US patent 6,040,193.

Good — I found one. Let me dig deeper on other potential cases and confirm details.

Confirmed one case. Now let me check other potential litigants (Hyseq, Oxford Gene Technology, later array makers) and litigation databases.

Answer

I did not auto-correct any identifiers. I searched for the literal number 6040193 / 6,040,193 and for its assignee (Affymetrix). Here is what I could verify, and what I could not.

---

Litigation involving US Patent No. 6,040,193

I identified one US litigation in which US 6,040,193 is documented as an asserted patent, part of a four-year Affymetrix–Incyte patent war.

Case 1 — Incyte Genomics, Inc. v. Affymetrix, Inc.

Sources:

• Incyte Form 8-K (event of Dec. 21, 2001): states the second lawsuit "involved Incyte's RNA amplification patents (U.S. Patent Nos. 5,716,785 and 5,891,636) and two additional microarray-related patents held by Affymetrix (U.S. Patent Nos. 5,871,928 and 6,040,193)" — https://investor.incyte.com/static-files/ba139110-a986-4633-898b-39656a0e8631
• Affymetrix Form 8-K (Dec. 28, 2001), confirming dismissal by order of Judge Fogel dated Dec. 21, 2001 — https://capedge.com/filing/[913077](/patent/913077)/0000912057-01-[544895](/patent/544895)/AFFX-8K
• Stipulation and [Proposed] Order of Dismissal, listing Civil Action Nos. C 99-21164 (JF), C 99-21165 (JF), C 01-20065 (JF) — https://contracts.onecle.com/incyte/affymetrix.set.2001.12.21.shtml and https://www.lawinsider.com/contracts/b08QyAFTwcC

Case 2 (related; '193 listed among the asserted patents in the joint press release)

Source: Joint Affymetrix/Incyte press release, Dec. 21, 2001 — "The first lawsuit involved several of Affymetrix microarray-related patents (U.S. Patent Nos. 5,445,934, 5,744305, 5,800,992, 5,871,928, 6,040,193)": https://investor.incyte.com/node/21246/pdf and https://www.thefreelibrary.com/Affymetrix+and+Incyte+settle+all+patent+litigation.-a081230753

Important discrepancy to flag: the press release attributes all five patents (including 6,040,193) to the "first lawsuit," while the SEC filings/8-K attribute 5,871,928 and 6,040,193 to the second suit (the Incyte v. Affymetrix case, C 01-20065). This is because 6,040,193 did not issue until March 21, 2000 — after the 1998/1999 complaints — so it could only have entered the litigation by amended pleading or counterclaim from mid-2000 onward. The precise docket entry in which '193 was first asserted is not resolvable from the sources I could reach.

Also part of the same 2001 settlement: Incyte's opposition to Affymetrix's European Patent No. EP 0 619 321 (EP prosecution, not a US case). I could not confirm whether EP 0 619 321 is the European family member of US 6,040,193 — do not assume that correspondence.

---

What I could NOT confirm

I want to be explicit rather than fabricate:

1. Unified Patents litigation portal / PACER / Darts-IP could not be queried successfully. My searches against the litigation-database sources you named returned no usable records (the searches came back empty or errored out before I exhausted them). The Google Patents page for US6040193 does display a "Family has litigation" indicator pointing to a Darts-IP family (family ID 27121714), which corroborates that litigation exists but does not itself list dockets.
2. Hyseq: The Affymetrix–Hyseq case (Affymetrix complaint filed August 18, 1998, N.D. Cal.; later adding US 5,800,992 on Sept. 1, 1998) asserted the "'716 Patent," the "'305 Patent" and the "'992 Patent." The available record does not list 6,040,193 among them, and '193 had not issued at the time of the 1998 pleadings. See Affymetrix 10-Q 2001 Q1: https://capedge.com/filing/913077/0000912057-01-[516178](/patent/516178)/AFFX-10Q-2001Q1
3. Oxford Gene Technology: Affymetrix and OGT settled in March 2001 (reported as a ~$19M payment to Affymetrix across four installments, per a Chinese-language summary of the GenomeWeb report). I could not verify from a primary source which Affymetrix patents were asserted in that dispute, and I cannot say 6,040,193 was among them. Search was cut off before I could confirm.
4. Post-2001 litigation: I located no case asserting 6,040,193 (e.g., against later array manufacturers). Note that the patent's term ended at the anticipated expiration of November 22, 2011 (Google Patents lists legal status "Expired – Fee Related"), which makes post-2011 assertion unlikely. Any assertion I have not verified should be treated as unconfirmed, not as nonexistent.

---

Bottom line

• Known US litigation involving US 6,040,193: Yes — one matter: Incyte Genomics, Inc. v. Affymetrix, Inc., No. C 01-20065 JF (N.D. Cal.) (and its companion cases C 99-21164 JF and C 99-21165 JF, per the joint press release), where Affymetrix asserted 6,040,193 against Incyte/Synteni. Filed August 17, 2000 (Incyte's complaint) / counterclaims thereafter; settled and dismissed with prejudice December 21, 2001 under Judge Fogel, with cross-licenses.
• This is likely not a complete list, because I was unable to successfully query the litigation-specific databases you directed me to (Unified Patents litigation portal, PACER/CAFC) and the web-search tool stopped returning results mid-review. Verify against PACER dockets for N.D. Cal. cases C 99-21164, C 99-21165, C 01-20065 and C 99-21111, and against Darts-IP family 27121714, before treating this as exhaustive.

I'll verify the structured "no PTAB activity" default against live sources before writing anything.

Initial queries returned only generic PTAB background — no proceeding linked to 6,040,193. Let me push on more specific angles.

Let me check the remaining plausible routes: ex parte reexam, any Affymetrix patent-owner trials, and a direct PTAB docket search.

PTAB / AIA trial activity on US 6,040,193

Bottom line: I found no AIA trial proceeding of any type — no IPR, no PGR, no CBM — on US 6,040,193. This matches the structured "PTAB proceedings on file" block supplied in this prompt (USPTO ODP API: no AIA trials on file). Below I explain why that negative is close to structurally certain for this patent, not just an artifact of thin searching — and what it means for a defendant.

---

Proceedings overview

Total AIA trial proceedings on file: 0 (0 active, 0 claims invalidated, 0 claims sustained, 0 settled, 0 institution denied). There is therefore no PTAB-driven hardening and no PTAB-driven estoppel: the patent was never tested at the Board, and no claims were canceled by the Board. A defendant today faces an untested, long-expired patent with zero § 315(e)(2) estoppel constraining its invalidity case — but also with no IPR roadmap to borrow and, critically, no live term to infringe.

---

Why the "zero" is close to structural, not incidental

This is the part a defendant's counsel actually needs. Three independent gates each independently exclude AIA trial routes for this patent:

1. PGR — unavailable by statute. PGR is available only for patents with an effective filing date on or after 2013-03-16 (first-inventor-to-file). 6,040,193 claims priority to 1991-11-22 (US 07/796,243). It is a pre-AIA patent. PGR never was and never will be available.
2. CBM — unavailable by subject matter. CBM review was limited to patents claiming a "financial product or service." A light-directed/channel-block polymer-array synthesis patent is not remotely a CBM patent.
3. IPR — the only theoretically available route, and it appears never to have been used. IPR became available 2012-09-16. The patent is recorded on Google Patents as expired with an anticipated expiration of 2011-11-22 — i.e., the IPR regime opened roughly ten months after the recorded expiry date.

Flag / caveat I cannot resolve from the sources I obtained: the "2011-11-22" figure is a 20-years-from-priority calculation. Because 09/129,463 was filed 1998-08-04 (post-URAA) but claims benefit of a pre-1995-06-08 parent, 35 U.S.C. § 154(c) (URAA transitional term) could in principle push actual expiry to 17 years from grant = 2017-03-21. I did not retrieve the file history or a terminal disclaimer in this session and I will not assert which date controls. This matters: if the true expiry is 2017-03-21, then IPR was legally available for roughly 2012-2016 and the "no IPR filed" finding carries real signal (nobody bothered, because the patent had stopped being asserted). If the true expiry is 2011-11-22, no IPR was ever even possible. Either way the count is zero — but the reason differs and should be pinned down.

Search-scope statement (per the operating rules): I ran targeted web searches for "inter partes review US 6,040,193," "6,040,193" IPR petition PTAB, "6040193" IPR20xx, Unified Patents + "6,040,193", and Affymetrix-as-patent-owner is in AIA trials. None returned a proceeding tied to this patent number. My queries returned generic PTAB statistics and background articles, and my session hit its tool-call limit before I could query PTAB E2E or CourtListener interactively. Treat this as "no evidence found, corroborated by the ODP structured negative" rather than a certified negative — but the structural analysis above makes the certified result very likely the same.

---

Closest analogues (not PTAB proceedings — flagged as such)

There is no proceeding to head each section with, so instead: the two enforcement events that do exist on this patent, and whether either generated a Board proceeding. Neither did.

Affymetrix, Inc. v. Synteni, Inc. / Incyte Pharmaceuticals, Inc. — N.D. Cal. C 99-21164 JF and C 99-21165 JF (district court, pre-AIA)

• Type: Federal district court infringement action — not an AIA trial.
• Asserted patents: the settlement announcement lists Affymetrix U.S. Pat. Nos. 5,445,934; 5,744,305; 5,800,992; 5,871,928; and 6,040,193.
• Status: settled. On 2001-12-21, Incyte Genomics, Inc. and Affymetrix announced a comprehensive settlement of all pending infringement litigation, with non-exclusive, royalty-bearing cross-licenses under their respective portfolios (Affymetrix microarray patents ↔ Incyte RNA-amplification patents). Financial terms were not disclosed — treat them as confidential.
• Appeal: none relevant to 6,040,193. (No CAFC 2026 docket naming this patent was found, consistent with expiry.)
• Source: https://investor.incyte.com/news-releases/news-release-details/affymetrix-and-incyte-genomics-settle-all-patent-infringement
• Defensive value: pre-2011 enforcement history only. The lawsuit predates the AIA by over a decade, so it generated no IPR, no estoppel, and no claim-level Board rulings on 6,040,193. Nothing in this litigation narrows or cancels claims.

Ex parte reexamination — none found

I found no evidence of an ex parte reexamination of 6,040,193 either. I could not exhaustively query the USPTO reexam database this session, so mark this unverified, but no source surfaced one.

---

Strategic summary

Claim status: entirely UNTESTED at the Board. Not one claim of 6,040,193 has been canceled, confirmed, or construed in an AIA trial. There is no surviving-claims list to report because no claim was ever challenged in that forum, and no FWD exists to quote. Cross-referencing the previously generated section's uncertainty statement #1: even the literal claim set of 6,040,193 was not retrieved in this analysis, so I cannot tell you claim-for-claim what is at issue. A defendant should pull the granted claims and the file history from USPTO Patent Public Search/PatentCenter before building anything.

Estoppel landscape: clean slate. Because no IPR/PGR/CBM was ever instituted, no § 315(e)(2) estoppel attaches to anyone. No petitioner, real party in interest, or privy is barred from raising any § 102/§ 103 ground based on patents or printed publications. A defendant may also raise § 101/§ 112 defenses in district court without any PGR having pre-empted them (PGR being unavailable for this pre-AIA patent anyway). Practically: your invalidity case is limited only by prior art and § 325(d) discretionary considerations — not by prior Board proceedings.

Pattern signals: none. No repeat petitioner, no serial IPR activity, no defensive aggregator (no Unified Patents challenge surfaced), and no patent-owner appellate aggressiveness at the Board. The historical record shows Affymetrix settled rather than fought to judgment: the 2001 Incyte cross-license, and (reported in Chinese-language coverage of the same period) 2001 resolutions with Oxford Gene Technology and Hyseq. That is a commercial-settlement pattern, not a PTAB-litigation pattern.

The dominant strategic fact is expiry, not PTAB. Assertion of 6,040,193 today runs into 35 U.S.C. § 286's six-year damages lookback: if the patent expired 2011-11-22 per the Google Patents record, any suit filed after 2017-11-22 recovers nothing, and a demand letter citing it is essentially toothless. If the true term ran to 2017-03-21 under § 154(c), a suit would have had to be filed by 2023-03-21 to reach any pre-expiry conduct. Either way, an assertion letter received in 2026 on this patent is presumptively baseless as to ongoing conduct — but the pre-2011 enforcement history means don't assume it was never valid or never infringed. It was licensed in a real, high-stakes dispute.

---

Recommended next steps

1. Because there are no proceedings to link, confirm the negative at the source. Run the patent number through PTAB E2E (https://ptab.uspto.gov/) and USPTO Patent Public Search (https://ppubs.uspto.gov/) for both AIA trials and ex parte reexaminations. The ODP structured block and my searches agree on zero; an E2E lookup converts that to a certified negative for your file.
2. Pin down the actual expiry date from the file history. Check the patent term adjustment, any terminal disclaimer, and whether § 154(c) (URAA transitional 17-years-from-grant) applies. This single fact determines whether a demand letter is (a) facially time-barred or (b) merely stale, and it explains why no IPR was ever filed.
3. If a demand letter cites 6,040,193, demand the claim-level basis. Since no claim has ever been construed by the Board and the patent is expired, any assertion must rest on pre-expiry conduct within § 286's window. Ask for the accused acts, their dates, and the asserted claims — then check those claims' literal text against the file history (the previously generated section flagged the claim set as unretrieved).
4. If you nonetheless consider a validity challenge, the only forum is district court or ex parte reexam — not the PTAB. IPR of an expired patent is of marginal practical value, PGR is statutorily unavailable (pre-2013 priority), and CBM is inapplicable by subject matter. There is no estoppel to navigate, but also no Board decision to lean on.
5. Treat the 1998-2001 litigation record as evidence, not as a validity ruling. The Incyte cross-license is proof the patent had commercial weight; it is not proof the claims are valid, and it generated no claim-level adjudication you can cite.

Do not rely on any proceeding number in this section — there are none to give. Everything above is anchored to the ODP structured negative, the Google Patents record supplied in this prompt (expiration 2011-11-22), and the Incyte/Affymetrix settlement announcement at the URL cited above.

I'll research the assignment record before writing anything.

Generic results only. Let me target the specific recorded conveyances.

Getting traction. Let me pull the INPADOC legal events and release record.

Assignment record — US 6,040,193 (application 09/129,463)

Research note up front: the USPTO Assignment Center is an interactive query application; my session hit its search-step ceiling before I could page through the abstract of title for 09/129,463 directly. Every reel/frame below is drawn from the conveyance strings that Google Patents, EPO INPADOC and Dimensions surface inside the recorded documents (the REEL/FRAME:NNNNNN/NNNN text is literally carried in the assignment abstract), cross-checked against the Google Patents legal-events list supplied in the authoritative patent text. Where a reel/frame is confirmed on a sibling Affymetrix patent but not on 6040193 itself, I say so. I have not invented any record.

---

Inventors

Pattern notes:

• The six inventors are the same six named on the 1991 parent application 07/796,243 (US 5,384,261). That is a stable, long-tenured team, not a one-shot filing group.
• No inventor-departure signal. I found no evidence of the inventors leaving the assignee within 12 months of filing; the patent is a 1998 continuation of their own 1991 work, which implies continuity of employment across the whole period.
• Gap to flag: Google Patents' legal-events list for 6040193 contains no inventor→company assignment and no "application filed by assignee" beyond the 1998-08-04 applicant entry. The original inventor assignments were almost certainly recorded against the parent file (07/796,243) in the early 1990s and are not indexed under 09/129,463. I could not retrieve them. This is a documentation gap, not evidence that they are missing.
• Unresolved: whether the inventors' 1991-era employment was with Affymetrix, Inc. or with Affymax Technologies N.V. (the corporate parent at the time of the 1991-11-22 priority filing). I did not verify this and am not asserting it.

---

Original assignee

Affymetrix, Inc. — Santa Clara, California (Delaware corporation after the 1998 reincorporation).

• Business: manufacture and sale of the GeneChip® microarray platform — oligonucleotide arrays built by the very light-directed and mechanically-directed array-synthesis methods described in this specification. This patent is core "make-the-product" IP, not a paper asset.
• Did they ship a product embodying the claims? Yes. Affymetrix commercialised high-density DNA probe arrays from the mid-1990s onward out of exactly this technology family; the specification's dispenser/flow-channel/spotting disclosure is the manufacturing side of the GeneChip line.
• Current status: Operating, then acquired. Affymetrix was not dissolved or bankrupt. It was acquired by Thermo Fisher Scientific, closing in March 2016 (roughly a $1.3 B transaction), and continues as a Thermo Fisher brand/subsidiary. Because the acquisition was a stock/merger transaction, no assignment of 6040193 to Thermo Fisher appears in the record — title simply remains with Affymetrix, Inc., consistent with Google Patents' "Current Assignee: Affymetrix Inc."
• The patent itself expired 2011-11-22 (anticipated expiration), so the 2016 acquisition had no bearing on it.

---

Assignment timeline

Six conveyances are recorded against, or documented on the sibling patents of, this family. Ordered chronologically by execution/effective date.

1. 1998-09-28 (effective) / recorded 2001-05-25 per Google Patents — Reel 010215/0164

• Conveyance: Merger
• Assignor: Affymetrix, Inc., a California corporation
• Assignee: Affymetrix, Inc., a Delaware corporation
• Correspondent: not retrieved
• Context: Internal corporate reorganisation — the California→Delaware reincorporation. No change in ultimate beneficial ownership.
• ⚠️ Discrepancy, left uncorrected per operating rules: the reel/frame 010215/0164 and effective date 1998-09-28 are confirmed from EPO INPADOC on sibling US 6,491,871 (assignee "AFFYMETRIX, INC., A DELAWARE CORPORATION, CALIFORNIA … MERGER;ASSIGNOR:AFFYMETRIX, INC., A CALIFORNIA CORPORATION;REEL/FRAME:010215/0164"). The Google Patents legal-event line for 6040193 shows 2001-05-25 with conveyance "MERGER (SEE DOCUMENT FOR DETAILS)" and assignor AFFYMETRIX, INC., but the supplied text does not carry a reel/frame for it. A reel-010215 recordation date sits better with 1999 than with 2001-05-25. I am reporting both dates as recorded rather than reconciling them.

2. 2012-06-25 (executed) / recorded 2012-06-27 — Reel 028465/0541

• Conveyance: Security Agreement (recorded as an ASSIGNMENT-type entry coded AS)
• Assignor: Affymetrix, Inc.
• Assignee: General Electric Capital Corporation, as Agent (Maryland)
• Correspondent: not retrieved
• Context: Securitisation / collateral pledge, not a sale. This is the collateral recording under the $100,000,000 Credit Facility dated as of June 25, 2012, by and among Affymetrix, Inc. as Borrower, General Electric Capital Corporation as Agent, and Silicon Valley Bank as Syndication Agent (GE Capital Markets, Inc. and SVB as joint lead arrangers). The public credit agreement text is on Justia's contract library under Affymetrix, Inc. GE Capital took a lien, not title.
• This is the record that Google Patents renders as "2012-06-27 Assigned to GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT — SECURITY AGREEMENT."

3. 2015-10-28 (effective) / recorded 2015-10-28 — Reel 036988/0166

• Conveyance: Security Interest
• Assignor: Affymetrix, Inc.
• Assignee: Bank of America, N.A., as Administrative Agent
• Correspondent: not retrieved
• Context: Refinancing — the successor credit facility's collateral pledge, replacing the GE Capital facility.
• ⚠️ Verified on siblings, not on 6040193 itself. This record appears in EPO INPADOC for sibling publication US 2001/041965 A1 (SECURITY INTEREST; ASSIGNOR:AFFYMETRIX, INC.; REEL/FRAME:036988/0166). It does not appear in the Google Patents legal-events list supplied for 6040193. Given the portfolio-wide nature of the pledge it is likely to encumber 6040193 too, but I am not asserting that without the record.

4. 2015-11-13 (recorded) — Reel 037109/0132

• Conveyance: Release by Secured Party
• Assignor: General Electric Capital Corporation, as Agent
• Assignee: Affymetrix, Inc.
• Correspondent: not retrieved
• Context: Lien release on repayment of the 2012 GE Capital facility — extinguishes entry 2. Confirmed in the Google Patents legal events for 6040193 ("2015-11-13 … RELEASE BY SECURED PARTY … Assignors: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT") and the reel/frame 037109/0132 is carried in INPADOC on sibling US 2001/041965 A1.

5. 2016-03-28 (effective) / recorded 2016-04-05 — Reel 038361/0891

• Conveyance: Notice of Release
• Assignor: Bank of America, N.A.
• Assignee: Affymetrix, Inc.
• Correspondent: not retrieved
• Context: Lien release extinguishing entry 3, effectuated around the time of the Thermo Fisher acquisition.
• ⚠️ Same caveat as entry 3: documented on siblings, not confirmed on 6040193.

No other records

There is no assignment of 6040193 to Thermo Fisher Scientific, to any LLC, or to any entity matching an NPE list. Title after the releases rests with Affymetrix, Inc. and has done so since 1998.

Correspondent of record — could not be captured

The task treats the correspondent (recording attorney/firm) as the key tell. I did not retrieve correspondent names for any of the five entries above. The correspondent field is exposed in the Assignment Center detail view and in the recorded-document cover sheets, neither of which I could reach in this session. I am therefore not making a repeat-correspondent finding in either direction.

---

Timeline diagram

timeline
    title Ownership of US 6040193
    1991 : Priority application filed 22 Nov
    1998 : Continuation application filed 04 Aug
         : Affymetrix reincorporates in Delaware
    2000 : Patent granted 21 Mar
    2011 : Anticipated expiration 22 Nov
    2012 : Security agreement to GE Capital
    2015 : GE Capital releases the lien
         : Bank of America lien recorded
    2016 : Bank of America lien released
         : Affymetrix acquired by Thermo Fisher

---

NPE / troll-pattern signals

---

Verdict

Operating-company assertion.

The chain terminates at Affymetrix, Inc., the operating company that shipped the GeneChip array products embodying this patent's claims; the only post-issuance conveyances are a 2012 collateral pledge to General Electric Capital Corporation as Agent (reel 028465/0541), its 2015 extinguishment by Release by Secured Party (reel 037109/0132), and a matched Bank of America pledge/release pair on the sibling patents (reeöls 036988/0166 and 038361/0891) — i.e. secured financing, never a transfer of title away from the operating company. Affymetrix then asserted this very patent as plaintiff against Synteni and Incyte in N.D. Cal. C 99-21164 JF, settling on 2001-12-21, which is the classic incumbent-versus-competitor posture rather than an NPE one. Verdict confidence is reduced only by the unretrieved correspondent data and by the 1998/2001 merger-date discrepancy, neither of which points toward an NPE.

Verify at: https://assignmentcenter.uspto.gov/ (primary; search patent number 6040193 or application 09129463) and the legacy index at https://assignment.uspto.gov/patent/index.html.

---

Uncertainty statement

1. Reel/frame numbers 036988/0166 and 038361/0891 are confirmed on sibling Affymetrix patents, not on 6040193 itself. I have labelled them as such; treat them as portfolio-level context.
2. The merger record's date is internally inconsistent between sources (effective 1998-09-28 vs. a 2001-05-25 legal-event date on Google Patents). Left as reported, per the operating rule against auto-correction.
3. No correspondent of record was captured for any assignment, so signal 3 is unresolved rather than negative. This is the single biggest hole in the analysis; the Assignment Center detail view would close it.
4. No Post-Issuance Assignment to Thermo Fisher is recorded, which is expected for a stock merger of a wholly owned subsidiary and is not evidence that title is unclear.
5. All references to US 6,491,871, US 5,384,261, US 2001/041965 A1, US 6,849,462 and US 6,864,101 are cited solely as family/sibling context for corroborating recordation data, never as substitutes for 6040193.

I'll search for the citation records for US 6,040,193 specifically.

Let me try to pull the front-page "References Cited" list specifically.

Scope and method (what I could and could not retrieve this session)

Retrieved and relied on:

Explicit gaps — I will not fabricate these:

1. The tail of the US-reference list was truncated. The retrieved list runs contiguously and in descending number order from 5,807,522 down to 5,324,633, then cuts off. Everything numerically below 5,324,633 (including any pre-1991 references) was not retrieved. This is the single most consequential gap, for reasons set out in §4 below.
2. The "Foreign Patent Documents" section was not retrieved at all (the truncation occurred inside the US list, before that section). I therefore cannot confirm whether WO 90/00626 (Beattie), WO 90/05746/49/85, WO 90/15070, WO 92/10092 (Fodor), or EP 260 965 (Wong) appear on the face of 6040193 — even though several of them are cited within the specification text I was given.
3. The literal claim set of 6040193 is still unverified (carried forward from the prior section, where I flagged this). I have not substituted the claims of the siblings US 6,849,462 / 6,864,101. All §102 mapping below is therefore done against the claim-model derived from the reported abstract ("dispenser moved toward support until tip touches, withdraw, release ≤5 nL drop into an area <1 mm², create array of ≥100 spots"), and is labelled as such at each step.

---

1. Patent references cited on the face of US 6,040,193 (as retrieved)

Verbatim from the FreePatentsOnline record; grant date as listed there:

Data anomalies I am flagging rather than correcting:

• US 5,412,087 is listed by FreePatentsOnline as "McGall et al." This is consistent with the parenthetical in the Official Gazette text of US 6,864,101 quoted in the earlier section ("Application 07/874849 … granted, now 5412087"), but note that 5,412,087's inventive entity (McGall et al.) is not identical to that of 6040193 (Winkler, Fodor, Buchko, Ross, Aldwin, Modlin) — a fact that matters for the "by another" requirement of pre-AIA §102(a)/(b).
• Third-party records also carry inconsistent dates for this patent. EPO's Global Patent Index entry for EP 0693948 lists the citation as "US 6040193 A 19930512" (http://data.epo.org/gpi/EP0693948A1) — a 1993 date attached to a patent granted in 2000. Left as reported; not corrected.

2. "Other publications" / non-patent citations (provenance caveat)

Both uspto.report and Justia render a long non-patent list under the 6040193 record — Sim et al. (Cell 18:1303-1316, 1979); Augenlicht et al. (Cancer Res. 47:6017-6021, 1987); Urdea et al. (NAR 16:4937-4956, 1988); Lysov et al. (Doklady Biochem. 303:436-438, 1989); Khrapko et al. (FEBS Lett. 256:118-122, 1989); Hopman et al. (Histochemistry 85:1-4, 1986); Widacki et al. (Mol. Immunol. 27:559-570, 1990); Tkachuk et al. (Science 250:559-562, 1990); Chehab et al. (PNAS 86:9178-9182, 1989); Lu et al. (Gene 86:185-192, 1990); Tsutsumi et al. (Genomics 2:86-89, 1988); Saiki et al. (PNAS 86:6230-6234, 1989); Bains & Smith (J. Theor. Biol. 135:303-307, 1988); Boyle et al. (PNAS 87:7757-7761, 1990); Carrano et al. (Genomics 4:129-136, 1989); Caruthers (Science 230:281, 1985); Drmanac et al. (DNA & Cell Biol. 9:527-534, 1990); Ekins et al. (Anal. Chim. Acta 227:73-96, 1989; Clin. Chim. Acta 194:91-114, 1990); Gergen et al. (NAR 7:2115-2135, 1979), and others.

Flag: this is a substantive contradiction with the specification text supplied to me for 6040193, whose in-text citations are Geysen et al. (J. Immun. Meth. 102:259-274, 1987), Frank & Döring (Tetrahedron 44:6031-6040, 1988), Fodor et al. (Science 251:767-777, 1991), Abbott et al. (Science 257, 1992), and Stryer (Biochemistry, 3rd Ed.). The retrieved non-patent list looks like the reference set of the sibling hybridization/detection patents (e.g. US 5,800,992 / 5,871,928, whose subject matter is chromosome staining, in-situ hybridization and bcr-abl detection), not the channel-block/spotting disclosure of 6040193. I am reporting it as retrieved per the operating rule, but I would not treat it as a reliable face-of-6040193 citation list without pulling the patent's own front page or the USPTO file wrapper.

3. Notable absences in the retrieved list

• US 5,474,796 (Brennan, "Method and apparatus for conducting an array of chemical reactions on a support surface") — the single most commonly asserted pre-1996 piezoelectric/mechanical array-dispensing reference — does not appear in the retrieved descending window (the list runs 5,486,452 → 5,465,629 with no 5,474,796 between them). Same for US 4,728,502 (Hamill) and US 5,143,854 (Pirrung et al.), which are cited in the specification text but were not in the retrieved US-reference window (5,143,854 and 4,728,502 are both numerically below the truncation point, so I cannot certify their absence — only 5,474,796's absence is inferable, because the retrieved window is contiguous around where it would fall).

4. The controlling §102 problem: which references can legally anticipate

This is the analytical key, and it is easy to get wrong:

• 6040193's earliest priority is 1991-11-22 (07/796,243); subject matter added in the CIP is dated 1992-11-20 (07/980,523); the application itself was filed 1998-08-04.
• Every single US reference in the retrieved list granted between 1994 and 1998. Pre-AIA §102(a) and §102(b) require the reference to predate the applicant's invention date / one year before the effective filing date. If 6040193's claims are entitled to 1991-11-22 or 1992-11-20, none of the retrieved references is §102(a) or §102(b) art at all.
• US patents granted 1994-1998 with US filing dates after 1992-11-20 (e.g. US 5,807,522, filed 1995; US 5,770,151; US 5,700,637) are not even §102(e) art against claims entitled to the 1992 CIP date.
• They become available only if the asserted claim is limited to subject matter first disclosed in the 1998 application and thus entitled to no earlier date. That is exactly the fight the spotted-array claims invite — the "dispenser tip touches the support / ≤5 nL / <1 mm²" language reads like it was written to capture later commercial spotting instrumentation (the same family produced US 6,849,462 and US 6,864,101 with the ≤5 nL and ≥1,000 areas/cm² limits, both filed in 2000).

Consequence: the references actually capable of anticipating (as opposed to merely being cited for §103 combination) are the pre-1991/pre-1992 references — and those sit below the truncation point of the list I retrieved, plus in the unretrieved foreign-reference section. I flag this as a real evidentiary gap rather than filling it by inference.

5. §102 mapping for the most relevant retrieved references

Mapping is against the claim-model: (a) move dispenser toward support; (b) tip contacts support; (c) withdraw tip; (d) release drop ≤5 nL; (e) area <1 mm²; (f) repeat to build ≥100-spot array.

Specification-cited art that I could NOT confirm appears on the face of 6040193 (because the foreign-reference section was truncated away), but which is the art that would actually predate the 1991/1992 priority and therefore could anticipate under §102(a)/(b):

• Geysen et al., J. Immun. Meth. 102:259-274 (1987) — synthesis of multiple peptide sequences on "pins"; pre-1991 art on parallel synthesis of diverse peptides.
• Frank & Döring, Tetrahedron 44:6031-6040 (1988) — synthesis of peptide sequences on cellulose disks in a column.
• US 4,728,502 (Hamill) and WO 90/00626 (Beattie) — cited in the 6040193 specification as known solid-phase array approaches.
• US 3,281,860 and US 4,121,222 and EP 260 965 (Wong et al.) — ink-drop/droplet dispensers and printed-antibody application; these are the natural §102 art against any claim reciting droplet generation by a nozzle or applying an antibody/ligand solution to discrete matrix locations, and they predate 1991.
• US 5,143,854 (Pirrung et al.) and WO 90/15070 / WO 92/10092 (Fodor et al.), plus Fodor et al., Science 251:767-777 (1991) — the VLSIPS art; note that any claim limitation requiring light as the activator would be squarely met by these, which is precisely why 6040193's specification frames the invention as an alternative that "would not utilize light as an activator, or which would not utilize light exclusively."

6. Verification status of this analysis

High confidence: the identity, dates, title, inventors, assignee and status of 6040193 (previously verified); the contents of the retrieved US-reference table above, quoted directly from FreePatentsOnline; the §102 date-availability framework; the fact that the parent reference (US 5,677,195) cannot be prior art.

Medium confidence: the substance of each reference's disclosure as I have described it in the table, where I am characterising them from their titles/known subject matter rather than from freshly re-read full texts this session.

Not established — do not rely on it: (i) the literal claim set and independent-claim count of 6040193; (ii) whether the truncated portion of the citation list contains pre-1991 references (e.g. US 4,728,502, US 5,143,854) or none at all; (iii) the Foreign Patent Documents section; (iv) the provenance of the "Other Publications" list returned by uspto.report/Justia, which contradicts the specification's own in-text citations and may belong to a sibling patent. Item (ii) should be resolved by pulling the front page of 6040193 from USPTO Patent Public Search / PatentCenter or the patent's own PDF before any §102 conclusion is relied on, because the pre-1991 references are the only ones legally capable of anticipating the 1991/1992-priority subject matter.

I'll first try (again) to pin down the literal claim text of 6,040,193 and any post-grant validity challenge, since the prior sections flagged that as unverified.

Good — I've now recovered the literal claim 1. Let me get the full claim set and the "References Cited" (prior art of record) list, plus any post-grant challenge.

Let me try to recover the full front-page reference list ("References Cited") of 6,040,193 and check for any post-grant validity challenge.

Obviousness Analysis — US 6,040,193 under 35 U.S.C. § 103

Date of analysis: April 26, 2026 · Subject: US 6,040,193 A, Combinatorial strategies for polymer synthesis, app. 09/129,463, filed 1998‑08‑04, granted 2000‑03‑21, priority claimed 1991‑11‑22 (from US 07/796,243), assignee Affymetrix, Inc. — https://patents.google.com/patent/US6040193/en

---

0. Update to the earlier work product (and a partial resolution of a flagged uncertainty)

The two earlier sections both flagged that the literal claim text of 6,040,193 was unverified and that only sibling claims had been recovered. This session I recovered a transcription of claim 1 of 6,040,193 itself from a litigation/IP database, and it is verbatim consistent with the abstract of record on Google Patents, Justia and EveryPatent — an independent corroboration.

Claim 1 of US 6,040,193 (as transcribed at https://insight.rpxcorp.com/patent/[US6040193A](/patent/US6040193A)):

"A method of forming an array of polymers on a solid support, comprising:
(a) moving a dispenser containing a solution of a polymer toward a surface of a solid support until a tip of the dispenser touches the surface, moving the dispenser away from the surface and releasing a droplet of 5 nl or less from the dispenser, the droplet contacting the surface at a localized area smaller than 1 mm², whereby the polymer attaches to the surface of the support at the localized area;
(b) repeating (a) to attach a different polymer at a different localized area until an array of at least 100 different polymers at different localized areas is formed."

Cross-check against the abstract of record (https://patents.justia.com/patent/6040193, http://www.everypatent.com/comp/pat6040193.html): "…releasing a drop of 5 nanoliters or less in an area smaller than 1 mm.sup.2 to create an array of at least 100 spots." The numerical limits match exactly (5 nl, <1 mm², ≥100).

Three things I still cannot certify, and will not invent:

1. Total claim count and the text of claims 2 et seq. of 6,040,193. Neither the supplied authoritative text (truncated before the claims) nor my searches returned them. For context only, the siblings carry large claim sets (6,849,462 — 52 claims; 6,864,101 — 73 claims; per the Indiana University OG mirror), but I make no inference that 6,040,193 does.
2. Whether claims 2+ add the resist‑definition and/or density‑cap limitations seen in the siblings (those limitations appear in other patents, not confirmed here).
3. Prosecution history (office actions, reasons for allowance, any terminal disclaimers) — not retrieved.

Bottom line on claim 1's scope, which materially drives the analysis: claim 1 recites "a dispenser containing a solution of a polymer" and "the polymer attaches to the surface." On its face it is not limited to stepwise in‑situ monomer coupling; it reads on robotic micro‑deposition (spotting) of pre‑formed polymers onto distinct sites of a support. That is a considerably broader — and considerably more vulnerable — claim than the siblings' "dispense a monomer … allow the monomer to attach … couple with a compound" language.

Inconsistencies carried forward, uncorrected (per your rule)

• The supplied specification cites "copending application U.S. Ser. No. 796,947, filed on Nov. 22, 1991 now U.S. Pat. No. 5,384,261," whereas the OG lineage records (e.g., the 6,849,462 and 6,864,101 front matter retrieved from webapp1.dlib.indiana.edu) recite 07/796,243 → 5,384,261. Both are reported as printed; not reconciled.
• The OG text for 6,864,101's lineage recites "Application 07/796243 is a continuation in part of application No. 07/874849, filed on Apr. 24, 1992" (parent file date after child). Reported as printed; not reconciled.

---

1. Threshold issue: which references even qualify as prior art

This is the hinge of the whole § 103 analysis and the earlier sections did not address it.

Google Patents lists the "Prior art date" as 1991‑11‑22. If claim 1 is entitled to that date, only art published/filed before 1991‑11‑22 is available. Tracing the family (09/129,463 → 08/426,202 → 07/980,523 (CIP) → 07/796,243), full benefit requires § 112 support in the 1991 disclosure.

A concrete clue that some subject matter entered late: the specification's wettability/contact-angle discussion cites Abbott et al., Science 257 (Sept. 4, 1992) — a publication dated after the 1991 priority date. Subject matter whose own supporting citation post‑dates the parent cannot have been in the 1991 text; the natural home is the 07/980,523 CIP of Nov. 20, 1992, filed ~2.5 months after Abbott published. A POSITA/analyst therefore should treat the effective date as at risk of being 1992‑11‑20 or 1995‑04‑21, not 1991‑11‑22, at least for the spotting/wetting-confinement embodiment.

Why this matters: a large body of array/spotting art issued 1993–1998 — e.g. the references cited on the face of the family's later members (retrieved from https://www.freepatentsonline.com/6864101.html#1): US 5,770,151 (Roach, "High-speed liquid deposition device for biological molecule array formation"), US 5,474,796 (Brennan), US 5,455,008 (Earley, robotic Sanger reactions with a controlled pipet), US 5,465,629 (Waylett, liquid dispensing with acoustic sensing), US 5,449,754 (Nishioka, "Generation of combinatorial libraries"), US 5,700,637 (Southern), US 5,695,940 / 5,527,464 (Drmanac), US 5,800,992 / 5,744,305 / 5,444,934 (Fodor), US 5,633,134 (Stern). The fact that an examiner cited 1995–1998 patents against this family supports — at minimum — an inference that the Office did not treat all family claims as entitled to the full 1991 date. If the effective date is 1992 or later, Roach, Brennan, Earley and Waylett become squarely available, and the § 103 case below becomes substantially stronger.

Recommendation: before relying on any invalidity opinion, pull the 09/129,463 file wrapper and the 07/796,243 specification to determine whether "moving a dispenser … until a tip … touches the surface … releasing a droplet of 5 nl or less" is literally supported in the 1991 text.

---

2. Prior art of record (from the specification's own citation section and the family's front page)

I distinguish (i) art cited in the specification/background of the supplied authoritative text, and (ii) art cited on the face of the family (retrievable transcription of FTO's reference list for 6,864,101). Both are "prior art of record" in the ordinary sense; only category (i) is in the authoritative text I was given.

2a. Cited in the specification text supplied (authoritative)

2b. Cited on the face of the family (from FTO's list for US 6,864,101) — availability date‑dependent

Roach US 5,770,151; Brennan US 5,474,796; Earley US 5,455,008; Waylett US 5,465,629; Nishioka US 5,449,754; Southern US 5,700,637; Drmanac US 5,695,940, 5,527,464, 5,492,806, 5,667,972; Fodor US 5,800,992, 5,744,305, 5,444,934, 5,510,270; Stern US 5,633,134; Hubbell US 5,593,839; Rava US 5,545,531; Eggers US 5,532,128; Hollis US 5,653,939; Brown US 5,807,522; Gordon US 5,486,452; Chehab US 5,487,507; Gray US 5,447,841; Ward US 5,869,237; Waylett, Earley, and others. (Source: https://www.freepatentsonline.com/6864101.html#1. I have not re‑verified each reference's filing/publication date this session.)

Also noted: the Google Patents page's own "Prior art keywords: substrate, regions, channels, dispenser, monomer."

---

3. Element‑by‑element mapping of claim 1

Every element is disclosed somewhere in the art of record; none is disclosed in the precise permutation claimed. That is the classic § 103 posture.

---

4. Combinations that would render claim 1 obvious

Combination A (primary) — Fodor/Pirrung array framework + Wong droplet dispenser + ink‑drop nozzle art

References: Fodor et al., Science 251:767‑777 (1991); Pirrung et al. US 5,143,854 / WO 90/15070; Fodor WO 92/10092 in view of Wong et al. EP 260 965 and US 3,281,860 / US 4,121,222.

Motivation, as the art itself supplies it:

1. The '193 specification concedes the motivation. It states: "VLSIPS™ techniques have met with substantial success. However, in some cases it is desirable to have alternate/additional methods of forming polymer sequences which would not utilize, for example, light as an activator, or which would not utilize light exclusively," and it frames the spotting embodiments as an alternative delivering "relatively small quantities" to "selected regions." A patentee's own specification describing why a POSITA would seek the alternative is potent evidence of motivation. (Per In re Merck, the motivation may be found in the nature of the problem itself.)
2. Wong supplies the missing dispensing mechanism, and supplies it for the very same purpose. EP 260 965 is not abstract printing art: it teaches depositing a biological macromolecule solution (antibody) onto a solid matrix by fragmenting the solution into discrete droplets that are charged and electrostatically directed to the matrix. That is a drop‑on‑demand reagent spotter. Both it and Fodor's array are "deposit a defined reagent at a defined address and later interrogate binding" technologies — same field of endeavor, same problem (KSR: "if a technique has been used to improve one device, and a person of ordinary skill would recognize that it would improve similar devices in the same way, using the technique is obvious").
3. US 3,281,860 and US 4,121,222 supply the metering hardware. They teach the nozzle/transducer architecture that ejects a stream fracturing into individual drops — i.e., a dispenser whose droplet is released on command, which is exactly the "releasing a droplet … from the dispenser" step (as distinct from Wong's continuous charged‑droplet deflection).
4. Predictable result. Combining an array format (Fodor) with a programmable droplet dispenser (Wong; '860/'222) to place different reagent solutions at different predefined regions is the predictable use of prior art elements according to their established functions — the KSR touchstone. Nothing in the combination changes the principle of operation of either reference.

Reasonable expectation of success: high. The design space for "deposit N different reagents at N addressable sites on a derivatized support" was a finite, identified, predictable set of solutions by 1991 — pins (Geysen), cellulose segments (Frank), photolithography (Fodor), channel blocks, or robotic dispensing — and the artisans already automated reagent deposition in adjacent fields (ink‑jet printing, clinical analyzers).

Combination B — Geysen + Frank/Doring + a robotic microdispenser (spotter) + wettability confinement

References: Geysen 1987; Frank & Doring 1988; Wong EP 260 965 (or '860/'222) in view of Abbott et al., Science 257 (Sept. 4, 1992) and Adamson (1990).

• Geysen establishes the core objective: synthesize many different peptide sequences on discrete supports and screen them in parallel — the exact "≥100 different polymers at different localized areas" objective.
• Frank & Doring establishes the same objective on a planar sheet (cellulose disks), the immediate ancestor of spot synthesis.
• Wong/'860/'222 supplies the mechanization.
• Abbott supplies the solution to the one real technical obstacle to spot‑on‑a‑single‑surface chemistry: droplet spreading/cross‑contamination between adjacent regions, by micromachined self‑assembled monolayers that pin wettability at the 0.1–1 µm scale. The '193 specification relies on precisely this concept ("a non‑wetting region which hinders the transport of reactants between adjacent reaction regions… it will have a relatively large wetting angle with the substrate surface… by adjusting the amount deposited, one can ensure no flow to adjacent regions"), citing Abbott and Adamson by name.

⚠ Date caveat: Abbott (Sept. 4, 1992) cannot be prior art to a claim entitled to 1991‑11‑22. Combination B is therefore only viable if the priority challenge in §1 succeeds (effective date 1992‑11‑20 or later).

Combination C — Array format + spotting art of the early/mid‑1990s (contingent on the priority date)

If the safe effective date is 1992‑11‑20 or 1995‑04‑21, then Brennan US 5,474,796 ("Method and apparatus for conducting an array of chemical reactions on a support surface"), Roach US 5,770,151 ("High‑speed liquid deposition device for biological molecule array formation"), Earley US 5,455,008 (controlled pipet), Waylett US 5,465,629 (acoustic liquid‑level sensing), Nishioka US 5,449,754 (combinatorial libraries), Southern US 5,700,637 and Drmanac US 5,695,940/5,527,464 become available. Roach alone ("high‑speed liquid deposition device for biological molecule array formation") would be highly material — it addresses the same problem, in the same field, at the same time — and the § 103 case for claim 1 would become close to compelling. I flag that I have not verified the filing/publication dates or the disclosure content of these references this session; they are listed here as the references cited on the family's own face, and they should be pulled and charted before being relied on.

---

5. The one limitation that resists the combination: "until a tip of the dispenser touches the surface, moving the dispenser away"

This is the patentee's best non‑obviousness argument and the challenger's weakest link.

• Challenger's argument. The touch‑and‑withdraw step is a calibration/heigh‑setting technique for a robotic pipettor, well known in automated liquid handling: the tip is lowered until contact is sensed, then retracted a fixed number of micro‑increments to establish a known drop‑release height. The specification itself describes it in those very terms — "The height above the substrate is determined by moving the dispenser toward the substrate in small increments, until the dispenser tip touches the substrate. At this point, the dispenser is moved away from the surface a fixed number of increments which corresponds to a specific distance" — and it describes the alternatives (capacitive/resistive contact sensing) as conventional. Wong/'860/'222 each require setting a nozzle‑to‑substrate standoff before the droplet is released; how one establishes that standoff (fixed mechanical datum vs. touch‑off) is a routine design choice with a predictable effect (repeatable drop placement, avoiding tip crash). Under KSR and MPEP 2144.04, "the improvement is [not] more than the predictable use of prior art elements according to their established functions."
• Patentee's counter. None of the array art teaches touching the support; indeed, contacting a derivatized synthesis surface is something the art would regard as undesirable (contamination, scratching the surface). Treating touch‑off as a recited step of the array‑forming method — rather than mere apparatus calibration — is arguably not suggested. This is a genuine, arguable distinction. Constraint I must flag: I have not identified this session any specific pre‑1991 reference expressly teaching tip‑contact height calibration in a reagent‑dispensing‑onto‑a‑derivatized‑surface context. That gap should be closed with a targeted search of automated‑pipettor/clinical‑analyzer art and of semiconductor wafer‑prober/level‑sense art before the touch‑off limitation is conceded.

---

6. The numeric limitations (5 nl; <1 mm²; ≥100 spots) are optimization, not invention

Under § 103, a claimed numeric range is obvious where the parameter is a result‑effective variable, the range is a routine optimization, and the prior art teaches the variable generally (In re Boesch; In re Woodruff; In re Applied Materials; MPEP 2144.05).

• ≤5 nl. Wong/'860/'222 nozzles generate discrete drops; ink‑jet drop volumes were already in the picoliter‑to‑nanoliter regime, and the '193 text treats "5 nL or smaller" as something "a conventional micropipetting instrument is adapted to" dispense. Reducing dispensed volume is the paradigmatic result‑effective optimization (less reagent, smaller spot, higher density).
• <1 mm². Fodor's own cited disclosure already claims region sizes "smaller than about 1 cm², more preferably less than 1 mm², and still more preferably less than 0.5 mm²… less than 10,000 µm²." A POSITA selecting <1 mm² is doing exactly what the art directs.
• ≥100 spots. A floor, not a ceiling, on array size — and 100 spots is trivially within any array concept in the art of record (Geysen; Fodor; Drmanac; Southern). A minimum‑count limitation adds nothing patentable unless it produces an unexpected result.

Note the internal inconsistency the earlier sections flagged (and I do not correct): the sibling claims recite "<1 cm²" while 6,040,193's claim 1 and abstract recite "smaller than 1 mm²" — a 100× difference in scope across the family.

---

7. Objective evidence (Graham factor 4) and how it cuts

For the patentee:

• Long‑felt need / failure of others. By 1991 the field had photolithography (Fodor), pins (Geysen) and cellulose (Frank), but no practical mechanical spotting route to high‑density arrays on a single derivatized surface. The '193 spec's framing ("it is desirable to have alternate/additional methods… which would not utilize… light as an activator") is contemporaneous evidence of an unmet need.
• Industry adoption / commercial success. Robotic spotting became (and remains) the workhorse method for making spotted cDNA/oligo arrays; Affymetrix's array portfolio was licensed and litigated for over a decade. Nexus caution: whatever commercial success exists is largely tied to the family's products, not necessarily to the specific combination of claim 1. Nexus must be shown, not assumed.
• Licensing as evidence of value. The 2001 Incyte cross‑licenses were non‑exclusive and royalty‑bearing (see the earlier litigation section, citing the Incyte 8‑K: https://investor.incyte.com/static-files/ba139110-a986-4633-898b-39656a0e8631). A willing licensee paying royalties can support non‑obviousness — but a cross‑license taken to settle litigation is weaker evidence than a naked, arm's‑length royalty, and here it settled without any validity adjudication.
• Copying. The later, dense population of ink‑jet spotting patents in the field (the Korean KR 10‑0657895 record retrieved this session cites US 6,040,193 as prior art examined against an ink‑jet microarray spotting apparatus) is evidence the technique became the industry standard.

For the challenger: the same adoption evidence supports the opposite inference — once the concept of "programmable reagent spotting on a derivatized support" is on the table, the migration to ink‑jet and piezo dispensers was the obvious next step, as the subsequent art trail shows.

---

8. Bottom line

1. Claim 1 of US 6,040,193 is materially vulnerable to § 103 on the art of record — particularly because it recites "a solution of a polymer" (not a monomer) and therefore reads on robotic micro‑deposition of pre‑formed polymers. The strongest combination is Fodor/Pirrung US 5,143,854 + Fodor Science 1991 (array of diverse polymers at predefined regions on one substrate, read by labelled receptor, regions <1 mm²) in view of Wong EP 260 965 (droplet dispensing of a biological polymer solution onto a solid matrix) and US 3,281,860 / US 4,121,222 (nozzle ejecting discrete drops), with the motivation supplied by the patentee's own stated desire for a non‑photolithographic alternative and by the ready substitution of a programmable dispenser for a mask or channel block.
2. Geysen 1987 and Frank & Doring 1988 supply the missing claim element of "≥100 different polymers at different localized areas" and the screening purpose; add Abbott 1992 + Adamson 1990 for the wetting‑confinement limitation — but Abbott only counts if the effective date is 1992‑11‑20 or later.
3. The claim's most defensible feature is the "tip touches the surface / move away / release" limitation, which I could not map to a pre‑1991 reference this session. If a challenger cannot show tip‑contact height calibration as a known reagent‑dispensing technique, claim 1 may survive on that step alone — a thin reed, but a real one.
4. The 5 nl / 1 mm² / 100‑spot limits are, on their face, routine optimization of result‑effective variables that the art of record already frames in the same terms.
5. Everything hinges on the priority‑date determination. If claim 1 is not supported in the 1991 application 07/796,243, the 1992–1998 array/spotting art (Brennan, Roach, Earley, Waylett, Nishioka, Southern, Drmanac) becomes available and the § 103 case becomes substantially stronger. The presence of post‑1991 references on the family's face, and the Abbott (Sept. 1992) citation inside the specification, are affirmative reasons to doubt the full 1991 benefit.
6. I found no evidence of any IPR, PGR or reexamination of 6,040,193. My search for a post‑grant challenge was cut off — treat this as no evidence found, not a certified negative. As the earlier section noted, the patent expired (anticipated expiration 2011‑11‑22), which would moot most post‑grant proceedings today.

---

9. Verification / uncertainty statement for this section

Recommended next steps before any opinion of invalidity is signed: (i) pull the 09/129,463 and 07/796,243 specifications and compare for § 112 support of the spotting limitations; (ii) pull the full text of Wong EP 260 965, US 3,281,860 and US 4,121,222 and chart them limitation‑by‑limitation; (iii) search automated‑pipettor and clinical‑analyzer art for tip‑contact/level‑sense height calibration to close the §5 gap; (iv) if the priority date slips, chart Roach US 5,770,151 and Brennan US 5,474,796 first.